CJC-1295 no DAC + Ipamorelin

CJC-1295 no DAC + Ipamorelin: A 5 + 5 mg blend of a no-DAC GHRH analogue and ipamorelin.

What is it?

A 5 + 5 mg blend of a no-DAC GHRH analogue and ipamorelin.

How it is studied

The components engage different growth-hormone-related pathways: GHRH and the ghrelin receptor.

What the evidence says

A mechanistic rationale is not proof of a clinical benefit for this exact combination. Studies of either ingredient do not validate the blend.

What remains uncertain

The no-DAC identity and 5 + 5 mg ratio are integral to this listing. CJC-1295 with DAC is not a substitute. Combined endocrine effects and long-term safety remain uncertain.

Sources & scope

Long-acting CJC-1295 study (2006)

Beck et al., postoperative-ileus trial (2014)

For in-vitro laboratory research only. Not for human or veterinary use.